📰 Roche Diagnostics News
Page 18 - Roche Diagnostics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Roche Diagnostics. Real-time updates on events, politics, business and more.
July 5, 2023
/PRNewswire/ -- The "United States Biopsy Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report...
July 4, 2023
In 2022, Bioprocessing Analytics Equipment Market revenue is expected to reach US$ 485.1 million. With a CAGR of 4.5%, the global market is expected to reach US$ 633.6 billion by 2028.2.7% of the worldwide biopharmaceutical equipment market is made up of Bioprocessing Analytics Equipment. Over the projection period,...
July 3, 2023
By Dr Allan Pamba – Executive Vice-President Diagnostics, Africa at Roche Diagnostics and Dr Amit N. Thakker, Executive Chairman at Africa...
June 30, 2023
/PRNewswire/ -- The "Clinical Diagnostics: Global Markets" report has been added to ResearchAndMarkets.coms offering. The clinical diagnostics market is...
June 27, 2023
Here are the 10 most recent FDA safety recalls for drugs and medical devices. Several may cause injury or even death if used despite the FDA warnings.
June 26, 2023
Patients, allied health professionals, academia, global health think-tank and corporate partners launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) to tackle heart disease in Asia SINGAPORE - Media OutReach - 26 June 2023 - Today, patient organizations, allied health professionals, academia, corporate partners and a global health think-tank came together to launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD...
June 26, 2023
New coalition formed to fight heart disease across Asia
June 26, 2023
The In Vitro Diagnostics Market demand is expected to grow at a 4.8% CAGR between 2023 and 2033. The market is expected to reach a value of US$ 129.9 billion by 2033, up from US$ 81.3 billion in 2023.The demand for improved IVD testing is being driven by advances in medical science and complex disorders. Furthermore...
June 24, 2023
SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.In a phase 3 randomized controlled trial, more than 60% of adults with obesity and type 2 diabetes lost at least 10% of their body weight at 72 weeks if they were
June 23, 2023
Denifanstat was well-tolerated and met primary endpoint in planned interim readout with 67% of treated patients achieving ≥30% reductions in liver fat at week 26 compared to 18% placebo (p<0.001)